ArticleBMJ open2023

Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.

Chunmei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.